LifeVantage (LFVN) Expected to Announce Earnings on Tuesday

LifeVantage (NASDAQ:LFVN - Get Free Report) will likely be announcing its quarterly earnings results before the market opens on Tuesday, January 28th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $51,900.00 billion for the quarter. LifeVantage has set its FY 2025 guidance at 0.700-0.800 EPS.Investors that are interested in registering for the company's conference call can do so using this link.

LifeVantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, hitting analysts' consensus estimates of $0.15. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%. The firm had revenue of $47.21 million for the quarter.

LifeVantage Trading Up 0.8 %

Shares of LFVN traded up $0.19 during mid-day trading on Thursday, reaching $23.97. The company's stock had a trading volume of 249,878 shares, compared to its average volume of 266,077. The stock has a market cap of $300.10 million, a P/E ratio of 74.91 and a beta of 0.82. LifeVantage has a 1-year low of $5.22 and a 1-year high of $27.38. The business has a 50-day simple moving average of $17.38 and a two-hundred day simple moving average of $12.51.

LifeVantage Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a dividend of $0.04 per share. The ex-dividend date was Monday, December 2nd. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.67%. LifeVantage's dividend payout ratio (DPR) is currently 50.00%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Lake Street Capital began coverage on shares of LifeVantage in a research report on Thursday, December 19th. They issued a "buy" rating and a $26.00 target price for the company. Craig Hallum assumed coverage on shares of LifeVantage in a report on Tuesday, January 14th. They set a "buy" rating and a $35.00 target price on the stock.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.